Now Available:
Watch video podcasts of the 2008 EULAR press conferences

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

MSK Report Coverage of the 2008 EULAR Congress:


Michael Schiff, MD presents "Abatacept provides an increasing magnitude of response over time in measures of rheumatoid arthritis disease activity: results from the Attest Trial" at the 2008 EULAR Congress

EULAR 2008: Steroids Injections May Prevent Rheumatoid Arthrits From Developing
A 3-week course of IM steroids may stop the progression of early rheumatoid arthritis...

EULAR 2008: Nearly Half of Undifferentiated Arthritis Patients Can Achieve Drug-Free Remission After 1 Year of MTX
The chance of achieving drug-free arthritis remission after 1 year of MTX therapy is 46% and is predicted by a negative ACPA status, no or low radiographic damage at baseline, increased age, and shorter disease duration...

EULAR 2008: Hip Fracture Hospitalizations Drop in US Despite Aging Population
New research conducted by a 17-year-old high school student suggests that the US is having a significant impact on the osteoporosis epidemic...

EULAR 2008: Longitudinal MRI Study Confirms that Rituximab Stops Progression in RA, Suggests Some Regression
Imaging studies done 1 year after rituximab (RTX) treatment for rheumatoid arthritis (RA) confirm that progression of joint damage was stopped, and suggest that there may even have been some regression of established damage...

EULAR 2008: Briobacept May Follow Rituximab as B-Cell Directed Treatment in Rheumatoid Arthritis
Briobacept, which targets B-cell activating factor (BAFF), can be given repeatedly to reduce CD19+CD27- B-cells in rheumatoid arthritis patients...

ENDO 2008: More Zoledronic Acid Fracture Reduction Data Reported at Endocrine Society Meeting
Yearly infusions of zoledronic acid 5 mg reduced fractures and increased bone mineral density (BMD) when administered with or without concomitant osteoporosis therapy...

New from PubMed: Treatment Adherence in Patients with RA and SLE
Many RA and SLE patients report problems with treatment adherence; race, education, and treatment side effects are the most influential factors on adherence...

BioPharm Business: Lilly, TransPharma Ink Licensing and Development Agreement for Transdermal PTH Program for Osteoporosis
Eli Lilly and TransPharma have entered into a licensing and development agreement for ViaDerm, an agent for the treatment of osteoporosis. Phase II clinical testing of the agent is currently underway...

Click here to remove your e-mail address from our mailing list. For questions and comments regarding this newsletter please contact .